IRIS
MOIA, RICCARDO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 2.576
EU - Europa 2.399
AS - Asia 1.735
SA - Sud America 219
Continente sconosciuto - Info sul continente non disponibili 145
AF - Africa 88
OC - Oceania 4
Totale 7.166
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 2.441
RU - Federazione Russa 752
IT - Italia 581
SG - Singapore 563
IE - Irlanda 293
CN - Cina 289
HK - Hong Kong 250
DE - Germania 212
VN - Vietnam 202
BD - Bangladesh 184
BR - Brasile 180
SE - Svezia 141
FR - Francia 131
IN - India 85
GB - Regno Unito 81
CA - Canada 73
UA - Ucraina 47
FI - Finlandia 41
BJ - Benin 40
KR - Corea 39
MX - Messico 35
PL - Polonia 27
ID - Indonesia 21
JP - Giappone 20
TR - Turchia 20
ZA - Sudafrica 17
AT - Austria 14
LT - Lituania 14
ES - Italia 13
NL - Olanda 13
IQ - Iraq 12
AR - Argentina 11
EC - Ecuador 9
SA - Arabia Saudita 9
CZ - Repubblica Ceca 8
ET - Etiopia 8
JM - Giamaica 8
CO - Colombia 7
CR - Costa Rica 7
IR - Iran 6
BE - Belgio 5
EG - Egitto 5
PH - Filippine 5
AU - Australia 4
KE - Kenya 4
MD - Moldavia 4
MY - Malesia 4
PE - Perù 4
PK - Pakistan 4
SV - El Salvador 4
UZ - Uzbekistan 4
VE - Venezuela 4
AL - Albania 3
CL - Cile 3
DK - Danimarca 3
HR - Croazia 3
NG - Nigeria 3
SY - Repubblica araba siriana 3
AO - Angola 2
CH - Svizzera 2
DZ - Algeria 2
GR - Grecia 2
GT - Guatemala 2
IL - Israele 2
KG - Kirghizistan 2
MA - Marocco 2
OM - Oman 2
RS - Serbia 2
SC - Seychelles 2
TT - Trinidad e Tobago 2
TW - Taiwan 2
AE - Emirati Arabi Uniti 1
AZ - Azerbaigian 1
BG - Bulgaria 1
BY - Bielorussia 1
DO - Repubblica Dominicana 1
EE - Estonia 1
GA - Gabon 1
GE - Georgia 1
HN - Honduras 1
HU - Ungheria 1
KZ - Kazakistan 1
LB - Libano 1
LV - Lettonia 1
MK - Macedonia 1
NI - Nicaragua 1
NP - Nepal 1
PA - Panama 1
PS - Palestinian Territory 1
PT - Portogallo 1
PY - Paraguay 1
SN - Senegal 1
TN - Tunisia 1
Totale 7.021
Salva come PNG Salva come JPEG
Città #
San Jose 353
Dublin 291
Hong Kong 248
Council Bluffs 246
Singapore 230
Ashburn 214
Columbus 120
Beijing 109
Los Angeles 101
Jacksonville 72
Lauterbourg 70
Chandler 66
Moscow 65
Novara 65
New York 64
Ho Chi Minh City 56
Hanoi 50
Boardman 49
Munich 47
Milan 45
Santa Clara 43
Buffalo 40
Cotonou 40
Piemonte 38
Seoul 34
St Louis 34
Helsinki 33
Lawrence 33
Princeton 33
Vercelli 32
San Bernardino 29
Orem 28
São Paulo 28
Turin 28
Frankfurt am Main 27
Toronto 27
Bremen 25
Dallas 24
Mexico City 23
Warsaw 23
Falkenstein 22
Wilmington 21
Chennai 19
Grafing 19
Houston 19
Chicago 18
Rome 18
Tornaco 18
Brooklyn 17
London 17
Tokyo 17
Atlanta 16
Phoenix 16
Denver 15
Nuremberg 15
Poplar 15
Montreal 14
Boston 13
Johannesburg 13
Podenzano 13
San Mateo 13
Hillsboro 12
Belo Horizonte 10
Mumbai 10
Ankara 9
Cassano Magnago 9
Naples 9
Redondo Beach 9
Addis Ababa 8
Genoa 8
Haiphong 8
Manchester 8
Roseto degli Abruzzi 8
Stockholm 8
Amsterdam 7
Augusta 7
Bologna 7
City of London 7
Da Nang 7
Gallarate 7
Ottawa 7
Shanghai 7
Turku 7
Ann Arbor 6
Bexley 6
Brno 6
Charlotte 6
Garland 6
Guangzhou 6
Hangzhou 6
Jakarta 6
Kingston 6
Menlo Park 6
Rimini 6
Rio de Janeiro 6
Roubaix 6
Strasbourg 6
West Jordan 6
Barnet 5
Berlin 5
Totale 3.810
Salva come PNG Salva come JPEG
Nome #
Molecular clustering on ctDNA improves the prognostic stratification of DLBCL patients compared to ctDNA levels 181
International Prognostic Score for Asymptomatic Early-stage Chronic Lymphocytic Leukemia 160
Immunoglobulin light chain mutational status refines IGHV prognostic value in identifying chronic lymphocytic leukemia patients with early treatment requirement 148
Clonally unrelated Richter syndrome are truly de novo diffuse large B-cell lymphomas with a mutational profile reminiscent of clonally related Richter syndrome 148
Targeting p53 in chronic lymphocytic leukemia 143
Active AKT signaling triggers CLL towards Richter's transformation via over-activation of Notch1 139
Biological and clinical implications of BIRC3 mutations in chronic lymphocytic leukemia 138
KMT2D mutations and TP53 disruptions are poor prognostic biomarkers in mantle cell lymphoma receiving high-dose therapy: a FIL study 127
Multiregional sequencing and circulating tumour DNA analysis provide complementary approaches for comprehensive disease profiling of small lymphocytic lymphoma 127
A leukemia-protective germline variant mediates chromatin module formation via transcription factor nucleation 124
An update on: molecular genetics of high-risk chronic lymphocytic leukemia 121
Anti-rasburicase antibodies induce clinical refractoriness by inhibiting the enzyme catalytic activity 119
Potential of BCL2 as a target for chronic lymphocytic leukemia treatment 116
Precision medicine management of chronic lymphocytic leukemia 116
Druggable Molecular Pathways in Chronic Lymphocytic Leukemia 116
Stiffer Spleen Predicts Higher Bone Marrow Fibrosis and Higher JAK2 Allele Burden in Patients With Myeloproliferative Neoplasms 115
High Mitophagy and Low Glycolysis Predict Better Clinical Outcomes in Acute Myeloid Leukemias 110
Survival risk score for real-life relapsed/refractory chronic lymphocytic leukemia patients receiving ibrutinib. A campus CLL study 110
Lymphocyte doubling time in chronic lymphocytic leukemia modern era: a real-life study in 848 unselected patients 110
A Rare Case of Life-Threatening Jaundice Caused by Epstein-Barr Virus Infection and Secondary Cold Agglutinin Syndrome Successfully Treated with Rituximab 106
CD49d promotes disease progression in chronic lymphocytic leukemia: new insights from CD49d bimodal expression 105
Redefining the prognostic likelihood of chronic lymphocytic leukaemia patients with borderline percentage of immunoglobulin variable heavy chain region mutations 105
Late relapse in patients with diffuse large B-cell lymphoma: impact of rituximab on their incidence and outcome 103
An acquired factor V inhibitor induced uncontrolled bleeding in a postsurgery patient 103
Impairment of the T cell memory response in chronic lymphocytic leukemia patients after SARS-CoV-2 vaccination 102
High reproducibility of spleen stiffness measurement by vibration-controlled transient elastography with a spleen-dedicated module 100
Prediction of outcomes in chronic lymphocytic leukemia patients treated with ibrutinib: Validation of current prognostic models and development of a simplified three-factor model 100
A Clinical Prognostic Model Based on Machine Learning from the Fondazione Italiana Linfomi (FIL) MCL0208 Phase III Trial 100
Therapeutic strategies and treatment sequencing in patients with chronic lymphocytic leukemia: An international study of ERIC, the European Research Initiative on CLL 98
High BECN1 Expression Negatively Correlates with BCL2 Expression and Predicts Better Prognosis in Diffuse Large B-Cell Lymphoma: Role of Autophagy 98
XPO1 mutations identify early‐stage CLL characterized by shorter time to first treatment and enhanced BCR signalling 95
Assessment of the 4-factor score: Retrospective analysis of 586 CLL patients receiving ibrutinib. A campus CLL study 94
Comparison of ibrutinib and idelalisib plus rituximab in real-life relapsed/resistant chronic lymphocytic leukemia cases 94
The Biology of Chronic Lymphocytic Leukemia: Diagnostic and Prognostic Implications 93
Prognostic value of clonal evolution identified by sequential FISH in untreated chronic lymphocytic leukaemia 92
CAT rs1001179 Single Nucleotide Polymorphism Identifies an Aggressive Clinical Behavior in Chronic Lymphocytic Leukemia 92
Inducible T-cell co-stimulator (ICOS) and ICOS ligand are novel players in the multiple-myeloma microenvironment 90
Lymphocyte Doubling Time As A Key Prognostic Factor To Predict Time To First Treatment In Early-Stage Chronic Lymphocytic Leukemia 90
Effectiveness of ibrutinib as first-line therapy for chronic lymphocytic leukemia patients and indirect comparison with rituximab-bendamustine: Results of study on 486 cases outside clinical trials 90
TP53 disruption as a risk factor in the era of targeted therapies: A multicenter retrospective study of 525 chronic lymphocytic leukemia cases 89
Rituximab, bendamustine, and cytarabine followed by venetoclax in older patients with high-risk mantle cell lymphoma (FIL_V-RBAC): a multicentre, single-arm, phase 2 study 88
Anatomical heterogeneity of residual disease in chronic lymphocytic leukemia treated with ibrutinib 87
Validation of a survival-risk score (SRS) in relapsed/refractory CLL patients treated with idelalisib–rituximab 86
Prognostic impact of TP53 mutation in newly diagnosed diffuse large B-cell lymphoma patients treated in the FIL-DLCL04 trial 86
Cerebrospinal fluid xanthochromia after pegasparaginase hepatotoxicity in B-cell acute lymphoblastic leukemia 86
Prevalence and clinical impact of clonal hematopoiesis of indeterminate potential (CHIP) in chronic lymphocytic leukemia and richter transformation 85
Prognostication in chronic lymphocytic leukemia 84
Liquid biopsy in hematological malignancies: current and future applications 83
Integration of [18F]FDG-PET radiomics with liquid biopsy improves outcome prediction in newly diagnosed diffuse large B-cell lymphoma 82
Different prognostic impact of recurrent gene mutations in chronic lymphocytic leukemia depending on IGHV gene somatic hypermutation status: a study by ERIC in HARMONY 77
Detection of early seeding of Richter transformation in chronic lymphocytic leukemia 77
Venetoclax therapy in chronic lymphocytic leukaemia patients relapsed after allogeneic haematopoietic stem cell transplantation 74
Correction: Different prognostic impact of recurrent gene mutations in chronic lymphocytic leukemia depending on IGHV gene somatic hypermutation status: a study by ERIC in HARMONY 74
Ibrutinib dose intensity in high-risk chronic lymphocytic leukemia 73
Reply to Aron P. Kater et al 73
Other malignancies in the history of CLL: an international multicenter study conducted by ERIC, the European Research Initiative on CLL, in HARMONY 69
HL-370 Fragmentóme Profiling Reveals Distinct Molecular Subgroups of Classic Hodgkin Lymphoma 69
CD49d expression is included in a revised 4‐factor model predicting outcome in patients with chronic lymphocytic leukemia treated with ibrutinib: A multicenter real‐world experience 67
Long-term benefit of IGHV mutated patients in a real-life multicenter cohort of FCR-treated chronic lymphocytic leukemia 66
Unraveling the Epigenetic Landscape of Mature B Cell Neoplasia: Mechanisms, Biomarkers, and Therapeutic Opportunities 65
A comprehensive genetic study of classic Hodgkin lymphoma using circulating tumor DNA 64
Molecular measurable residual disease by immunoglobulin gene rearrangements on circulating tumor DNA predicts outcome in diffuse large B-cell lymphoma 62
null 62
Innovative Use of Fostamatinib in Managing Refractory Immune Thrombocytopenia in an HIV ‐Positive Patient: A Case Report 61
Liquid Biopsy in B and T Cell Lymphomas: From Bench to Bedside 58
Updated revision of the British Society of Haematology guidelines for chronic lymphocytic leukaemia 58
The VLA-4 integrin is constitutively active in circulating chronic lymphocytic leukemia cells via BCR autonomous signaling: a novel anchor-independent mechanism exploiting soluble blood-borne ligands 56
The immunomodulatory molecule TIGIT is expressed by chronic lymphocytic leukemia cells and contributes to anergy 55
Central Nervous System Involvement in CLL: An International Retrospective Study by ERIC, the European Research Initiative on CLL 54
Bispecific Monoclonal Antibodies in Diffuse Large B-Cell Lymphoma: Dawn of a New Era in Targeted Therapy 53
Dissecting clonal hematopoiesis in the myeloid compartment of chronic lymphocytic leukemia and Richter transformation 45
The time to first treatment is an independent predictor of overall survival in chronic lymphocytic leukemia 42
The integration of gene mutations and copy number variations refines the prognosis of mantle cell lymphoma: long-term results of the Fondazione Italiana Linfomi MCL0208 clinical trial 40
Diagnostic Challenges in a Young Man with a Suspected Mast Cell Disorder, Dysplastic Bone Marrow Morphology, and a ZRSR2 Mutation 38
ATM aberrations in chronic lymphocytic leukemia: del(11q) rather than ATM mutations is an adverse-prognostic biomarker 37
Disease-specific U1 spliceosomal RNA mutations in mature B-cell neoplasms 34
Richter transformation in diffuse large B-cell lymphoma in patients with chronic lymphocytic leukemia receiving ibrutinib: risk factors and outcomes 25
Clinical Frailty Scale as a Predictor of Early Treatment Discontinuation in Elderly Patients With Chronic Lymphocytic Leukemia Treated With Zanubrutinib: A Multicenter Real-World Study 23
Electronic case report forms generation from pathology reports by ARGO, automatic record generator for onco-hematology 22
Real-life efficacy and safety of vemurafenib plus rituximab in relapsed or refractory hairy-cell leukemia: A multicenter Italian retrospective study (HCL-PG03R) 21
Real-world safety and effectiveness of zanubrutinib vs ibrutinib in CLL: the CLL-ZANU2024 Italian cohort 16
Liquid biopsy in lymphomas: a potential tool for refining diagnosis and disease monitoring 16
Molecular Mechanisms of Resistance to Bispecific Antibodies in Diffuse Large B-Cell Lymphoma 16
No lymphocytosis increase after cBTKi is a rare phenomenon except for CD49d positive CLL mainly expressed in trisomy 12 16
Secondary Genetic Events and Their Relationship to TP53 Mutation in Mantle Cell Lymphoma: A Sub-Study from the FIL_MANTLE-FIRST BIO on Behalf of Fondazione Italiana Linfomi (FIL) 15
Clonal hematopoiesis dynamics influences long‐term outcomes of follicular lymphoma: Results from FIL FOLL12 trial 15
Familial forms of chronic lymphocytic leukemia have a worse prognosis than sporadic forms: an Italian case-control study 14
Molecular Pathogenesis and Targeted Treatment of Richter Transformation 14
Long-term follow-up of rituximab plus bendamustine and cytarabine in older patients with newly diagnosed MCL 13
Longitudinal Monitoring of Measurable Residual Disease in Chronic Lymphocytic Leukemia Patients Treated With Venetoclax: Results of a Prospective Multicenter Real-Life Study 13
Assessing prognosis of chronic lymphocytic leukemia using biomarkers and genetics 10
Clinical Outcomes in Double-Exposed Chronic Lymphocytic Leukemia Patients in Italy 10
Rethinking the feasibility and safety of venetoclaxobinutuzumab in chronic lymphocytic leukemia: nontraditional factors may play a role in clinical practice 10
Risk of hepatitis B virus reactivation in chronic lymphocytic leukemia patients receiving ibrutinib with or without antiviral prophylaxis. A retrospective multicentric GIMEMA study 8
Molecular biomarkers as key determinants of outcome in mantle cell lymphoma: results from the FIL V-RBAC trial 7
Venetoclax-based regimens in octogenarian patients with CLL: efficacy, safety, and comparison to BTKi in a multicenter cohort 5
Totale 7.166
Salva come PNG Salva come JPEG
Categoria #
all - tutte 35.720
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 35.720
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022241 0 5 10 11 21 3 24 3 6 25 63 70
2022/2023633 43 33 51 10 39 44 32 30 277 6 51 17
2023/2024359 28 29 33 12 44 11 46 4 1 17 38 96
2024/2025997 16 12 70 14 37 51 89 224 188 85 37 174
2025/20264.059 176 126 217 442 425 277 563 606 305 336 372 214
2026/2027619 276 343 0 0 0 0 0 0 0 0 0 0
Totale 7.166